Eisai Revenue

Eisai had revenue of 195.99B JPY in the quarter ending September 30, 2024, with 10.97% growth. This brings the company's revenue in the last twelve months to 753.22B, down -0.80% year-over-year. In the fiscal year ending March 31, 2024, Eisai had annual revenue of 741.75B, down -0.36%.

Revenue (ttm)

753.22B

Revenue Growth

-0.80%

P/S Ratio

1.64

Revenue / Employee

68.06M

Employees

11,067

Market Cap

1,216.63B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2024	741.75B	-2.65B	-0.36%
Mar 31, 2023	744.40B	-11.82B	-1.56%
Mar 31, 2022	756.23B	110.28B	17.07%
Mar 31, 2021	645.94B	-49.68B	-7.14%
Mar 31, 2020	695.62B	52.79B	8.21%
Mar 31, 2019	Pro	Pro	Pro
Mar 31, 2018	Pro	Pro	Pro
Mar 31, 2017	Pro	Pro	Pro
Mar 31, 2016	Pro	Pro	Pro
Mar 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Eisai News

10 days ago - Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia - Benzinga
16 days ago - Biogen Inc (BIIB) and Eisai's Alzheimer's Drug LEQEMBI Approved in Mexico - GuruFocus
4 weeks ago - Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Benzinga
5 weeks ago - Eisai wins orphan drug status for Lenvima for esophageal cancer - Seeking Alpha
5 weeks ago - Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease - PRNewsWire
5 weeks ago - Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug - MarketWatch
5 weeks ago - Biogen gains as Eisai wins EU nod for Alzheimer’s drug - Seeking Alpha
5 weeks ago - EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen - Reuters

More News